I promise

"I promise, Suzy... Even if it takes the rest of my life." -Nancy G. Brinker, Founder of Susan G. Komen for the Cure

What is TNBC

WHAT IS TRIPLE NEGATIVE BREAST CANCER?

Just in recent years, Triple Negative Breast Cancer (TNBC) has sparked interest in the news where instead of calling the tumor as ER-negative, PR-negative, and HER2-negative; researchers began using the shorthand term, "Triple Negative," dubbed the "new type" of breast cancer. Being Triple Negative, you don't have a targeted therapy and your only treatment option is chemotherapy.

Triple Negative Breast Cancer is seen in about 15% of all breast cancers. TNBC is a very aggressive cancer that tends to strike younger women, pre-menopause, especially among African-American women and women who have BRCA1 mutations. The tumor tends to be fast growing and is less likely to show up on an annual mammogram. TNBC is more likely to metastasis early on; has a high rate of recurrence in the first 2-3 years from diagnosis and has a poorer prognosis than other types of breast cancer due to lack of specific, targeted treatment for TNBC.

Monday, January 11, 2016

Study identifies first potential targeted drug for triple-negative breast cancer and uncovers drug-resistance mechanism - Dana-Farber Cancer Institute | Boston, MA


“We found that a class of agents known as BET bromodomain inhibitors
significantly impeded the growth of triple-negative breast cancer cells
in laboratory as well as animal-model tests,” says the study’s senior
author, Kornelia Polyak, MD, PhD,
of Dana-Farber. “On the basis of these results, such inhibitors will be
tested in patients with triple-negative breast cancer [TNBC] in a phase
2 study and they are also included in ongoing phase 1 trials."...

Click on link below to full story:
Study identifies first potential targeted drug for triple-negative breast cancer and uncovers drug-resistance mechanism - Dana-Farber Cancer Institute | Boston, MA
Posted by
Labels: , ,

Total Pageviews



"click image to link"